A detailed history of Financial Management Professionals, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Financial Management Professionals, Inc. holds 70 shares of VRTX stock, worth $28,572. This represents 0.0% of its overall portfolio holdings.

Number of Shares
70
Previous 66 6.06%
Holding current value
$28,572
Previous $31,000 6.45%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 24, 2024

BUY
$460.0 - $505.78 $1,840 - $2,023
4 Added 6.06%
70 $33,000
Q1 2024

Apr 16, 2024

SELL
$407.69 - $446.08 $4,076 - $4,460
-10 Reduced 13.16%
66 $28,000
Q4 2023

Jan 12, 2024

BUY
$343.0 - $410.68 $4,459 - $5,338
13 Added 20.63%
76 $31,000
Q2 2023

Jul 10, 2023

BUY
$314.42 - $351.91 $2,200 - $2,463
7 Added 12.5%
63 $22,000
Q1 2023

Apr 13, 2023

SELL
$283.23 - $323.1 $4,814 - $5,492
-17 Reduced 23.29%
56 $18,000
Q4 2022

Jan 11, 2023

BUY
$285.76 - $321.48 $4,000 - $4,500
14 Added 23.73%
73 $21,000
Q2 2022

Jul 12, 2022

BUY
$234.96 - $292.55 $4,699 - $5,851
20 Added 51.28%
59 $17,000
Q1 2022

Apr 27, 2022

BUY
$221.42 - $260.97 $8,192 - $9,655
37 Added 1850.0%
39 $10,000
Q2 2021

Aug 05, 2021

BUY
$187.49 - $221.1 $374 - $442
2 New
2 $0
Q1 2021

Apr 26, 2021

SELL
$207.02 - $241.31 $8,280 - $9,652
-40 Closed
0 $0
Q4 2020

Feb 03, 2021

SELL
$207.01 - $276.09 $28,774 - $38,376
-139 Reduced 77.65%
40 $9,000
Q3 2020

Oct 26, 2020

SELL
$255.65 - $303.1 $255 - $303
-1 Reduced 0.56%
179 $49,000
Q2 2020

Jul 21, 2020

BUY
$225.48 - $295.8 $40,586 - $53,244
180 New
180 $52,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Financial Management Professionals, Inc. Portfolio

Follow Financial Management Professionals, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Management Professionals, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Management Professionals, Inc. with notifications on news.